Remodeled CAR T-Cell Therapy Causes Fewer Side Effects - National Cancer Institute
A remodeled CAR T-cell therapy causes fewer neurologic side effects and is equally effective as the original form of the therapy, according to results from the first clinical trial of the treatment in patients with B-cell lymphomas. The CAR T-cell targets the CD19 antigen on cancer cells.